> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Updates Records for Recent EUAs
- URL: https://www.fdaweb.com/fda-updates-records-for-recent-euas/
- Published: 2021-02-19T12:00:00.000Z
- Updated: 2026-09-14T16:47:41.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5148705

*Federal Register* notice: FDA is updating its records to reflect five recent Emergency Use Authorizations (EUAs) for drug and biological products for use during the Covid–19 pandemic. FDA issued EUAs to: Baxter for Regiocit; HHS for Covid–19 convalescent plasma; , Eli Lilly for bamlanivimab; Regeneron Pharmaceuticals for casirivimab and imdevimab; and Eli Lilly for Olumiant (baricitinib) for use in combination with Veklury (remdesivir). The EUAs’ terms and conditions can be found [here](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization?ref=fdaweb.com).